Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
13 hedge funds and large institutions have $558K invested in Petros Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.02% → 0.01% (-0%)
8% less call options, than puts
Call options by funds: $12K | Put options by funds: $13K
19% less funds holding
Funds holding: 16 → 13 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
57% less capital invested
Capital invested by funds: $1.3M → $558K (-$744K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$90.7K |
| 2 |
VF
Virtu Financial
New York
|
+$53.6K |
| 3 |
V
Veritable
Wilmington,
Delaware
|
+$16.8K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$13.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$205K |
| 2 |
Two Sigma Investments
New York
|
-$162K |
| 3 |
Two Sigma Advisers
New York
|
-$115K |
| 4 |
BlackRock
New York
|
-$26.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8K |
PTPI Hedge Fund Activity: Q2 2022 in Review
13 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q2 2022, worth a combined $558K — down 57% from $1.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PTPI and 3 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $90.7K. The largest seller was Marshall Wace, exiting entirely with an estimated $205K sold.
- 13 institutional investors held Petros Pharmaceuticals (PTPI) as of Q2 2022, down from 16 in Q1 2022.
- Funds reported $558K of Petros Pharmaceuticals stock for Q2 2022, down 57% quarter-over-quarter.
- 3 funds opened new Petros Pharmaceuticals positions in Q2 2022 and 6 closed out, a net change of -3 holders.
- The largest Petros Pharmaceuticals buyer in Q2 2022 was Susquehanna International Group, an estimated $90.7K added.
- The largest Petros Pharmaceuticals seller in Q2 2022 was Marshall Wace, an estimated $205K sold.
Based on aggregated 13F filings for Q2 2022.